COVID-19 pneumonia. COVID-19, virus identified
Conditions
Interventions
Intervention 1: Intervention group: Patients received 5 ml/kg body weight / day Pentaglobin (Biotest company, Germany) for 3 consecutive days. Patients also received standard treatment and supportive
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Laboratory COVID-19 confirmed with RT-PCR who has acute respiratory distress syndrome Severely ill patient Oxygen saturation < 93% Not responding to national protocol after 72 hours Bilateral pulmonary infiltration Signed the consent form
Exclusion criteria
Exclusion criteria: Chronic kidney disease (stage 4, 5) Chronic liver disease (Child pugh C) Allergy to human immunoglobulins IgA defficiency
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Need for invasive mechanical ventilation. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record.;Death. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record.;Supportive treatment with non-invasive oxygen. Timepoint: 14 and 28 days after therapy initiation. Method of measurement: Medical record. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospitalization duration. Timepoint: 28 days after admission. Method of measurement: Medical records.;Ventilation duration. Timepoint: 7 and 14 days after admission. Method of measurement: Medical record. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactPayam Tabarsi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed